These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 23308083)
1. Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Sweeney EE; McDaniel RE; Maximov PY; Fan P; Jordan VC Horm Mol Biol Clin Investig; 2012 Feb; 9(2):143-163. PubMed ID: 23308083 [TBL] [Abstract][Full Text] [Related]
2. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. McDaniel RE; Maximov PY; Jordan VC Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002 [TBL] [Abstract][Full Text] [Related]
3. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? Jordan VC J Clin Oncol; 2008 Jun; 26(18):3073-82. PubMed ID: 18519949 [TBL] [Abstract][Full Text] [Related]
4. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505 [TBL] [Abstract][Full Text] [Related]
5. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273 [TBL] [Abstract][Full Text] [Related]
6. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929 [TBL] [Abstract][Full Text] [Related]
7. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer. Jan R; Huang M; Lewis-Wambi J Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593 [TBL] [Abstract][Full Text] [Related]
8. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337 [TBL] [Abstract][Full Text] [Related]
9. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Jordan VC; Lewis-Wambi JS; Patel RR; Kim H; Ariazi EA Breast; 2009 Oct; 18 Suppl 3(Suppl 3):S10-7. PubMed ID: 19914527 [TBL] [Abstract][Full Text] [Related]
10. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611 [TBL] [Abstract][Full Text] [Related]
11. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Jordan VC Endocr Relat Cancer; 2015 Feb; 22(1):R1-31. PubMed ID: 25339261 [TBL] [Abstract][Full Text] [Related]
12. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094 [TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401 [TBL] [Abstract][Full Text] [Related]
14. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645 [TBL] [Abstract][Full Text] [Related]
15. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor. Biswas DK; Averboukh L; Sheng S; Martin K; Ewaniuk DS; Jawde TF; Wang F; Pardee AB Mol Med; 1998 Jul; 4(7):454-67. PubMed ID: 9713824 [TBL] [Abstract][Full Text] [Related]
16. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Jordan VC; Brodie AM Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390 [TBL] [Abstract][Full Text] [Related]
17. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently? Bhattacharya P; Abderrahman B; Jordan VC Expert Rev Anticancer Ther; 2017 Apr; 17(4):297-310. PubMed ID: 28281842 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro. Gu W; Dong N; Wang P; Shi C; Yang J; Wang J Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]